Cargando…
Acquired hemophilia A in the setting of dual anticoagulation therapy and lupus anticoagulant: a case report
BACKGROUND: Acquired hemophilia A is a disorder caused by autoantibodies against coagulation factor VIII that may present with severe bleeding. We report a rare case of acquired hemophilia A presenting with coexisting lupus anticoagulant. CASE PRESENTATION: An 81-year-old Caucasian female presented...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063298/ https://www.ncbi.nlm.nih.gov/pubmed/35501873 http://dx.doi.org/10.1186/s13256-022-03402-x |
_version_ | 1784699135479250944 |
---|---|
author | Chen, Victor Roby, Lauren C. Wentzel, Stephanie Li, Mingjia Jones, Nicholas |
author_facet | Chen, Victor Roby, Lauren C. Wentzel, Stephanie Li, Mingjia Jones, Nicholas |
author_sort | Chen, Victor |
collection | PubMed |
description | BACKGROUND: Acquired hemophilia A is a disorder caused by autoantibodies against coagulation factor VIII that may present with severe bleeding. We report a rare case of acquired hemophilia A presenting with coexisting lupus anticoagulant. CASE PRESENTATION: An 81-year-old Caucasian female presented with large ecchymoses over the torso and extremities in the setting of an enoxaparin bridge to warfarin. Anticoagulation was held, but she continued to develop bruises with significant anemia and prolonged coagulation studies that failed to correct with mixing. Workup revealed factor VIII activity < 1% and a positive lupus anticoagulant. Initial testing for a factor VIII inhibitor was confounded by the presence of lupus anticoagulant, requiring a chromogenic Bethesda assay to confirm the presence of the inhibitor, establishing the diagnosis of acquired hemophilia A. The patient was initially treated with oral prednisone 80 mg daily and factor VIII inhibitor bypassing activity 25 units/kg twice daily before transitioning to susoctocog alfa 50 units/kg twice daily after placement of a tunneled line for outpatient rituximab infusions. On discharge, the patient’s ecchymoses were resolving and factor VIII levels improved. Following completion of rituximab therapy, the patient’s factor VIII activity normalized and factor VIII inhibitor was suppressed. CONCLUSIONS: Diagnosis of acquired hemophilia A can be confounded by other causes of abnormal coagulation studies and may require specialized testing, such as a chromogenic Bethesda assay, to confirm the presence of a factor VIII inhibitor. |
format | Online Article Text |
id | pubmed-9063298 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-90632982022-05-04 Acquired hemophilia A in the setting of dual anticoagulation therapy and lupus anticoagulant: a case report Chen, Victor Roby, Lauren C. Wentzel, Stephanie Li, Mingjia Jones, Nicholas J Med Case Rep Case Report BACKGROUND: Acquired hemophilia A is a disorder caused by autoantibodies against coagulation factor VIII that may present with severe bleeding. We report a rare case of acquired hemophilia A presenting with coexisting lupus anticoagulant. CASE PRESENTATION: An 81-year-old Caucasian female presented with large ecchymoses over the torso and extremities in the setting of an enoxaparin bridge to warfarin. Anticoagulation was held, but she continued to develop bruises with significant anemia and prolonged coagulation studies that failed to correct with mixing. Workup revealed factor VIII activity < 1% and a positive lupus anticoagulant. Initial testing for a factor VIII inhibitor was confounded by the presence of lupus anticoagulant, requiring a chromogenic Bethesda assay to confirm the presence of the inhibitor, establishing the diagnosis of acquired hemophilia A. The patient was initially treated with oral prednisone 80 mg daily and factor VIII inhibitor bypassing activity 25 units/kg twice daily before transitioning to susoctocog alfa 50 units/kg twice daily after placement of a tunneled line for outpatient rituximab infusions. On discharge, the patient’s ecchymoses were resolving and factor VIII levels improved. Following completion of rituximab therapy, the patient’s factor VIII activity normalized and factor VIII inhibitor was suppressed. CONCLUSIONS: Diagnosis of acquired hemophilia A can be confounded by other causes of abnormal coagulation studies and may require specialized testing, such as a chromogenic Bethesda assay, to confirm the presence of a factor VIII inhibitor. BioMed Central 2022-05-03 /pmc/articles/PMC9063298/ /pubmed/35501873 http://dx.doi.org/10.1186/s13256-022-03402-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Case Report Chen, Victor Roby, Lauren C. Wentzel, Stephanie Li, Mingjia Jones, Nicholas Acquired hemophilia A in the setting of dual anticoagulation therapy and lupus anticoagulant: a case report |
title | Acquired hemophilia A in the setting of dual anticoagulation therapy and lupus anticoagulant: a case report |
title_full | Acquired hemophilia A in the setting of dual anticoagulation therapy and lupus anticoagulant: a case report |
title_fullStr | Acquired hemophilia A in the setting of dual anticoagulation therapy and lupus anticoagulant: a case report |
title_full_unstemmed | Acquired hemophilia A in the setting of dual anticoagulation therapy and lupus anticoagulant: a case report |
title_short | Acquired hemophilia A in the setting of dual anticoagulation therapy and lupus anticoagulant: a case report |
title_sort | acquired hemophilia a in the setting of dual anticoagulation therapy and lupus anticoagulant: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063298/ https://www.ncbi.nlm.nih.gov/pubmed/35501873 http://dx.doi.org/10.1186/s13256-022-03402-x |
work_keys_str_mv | AT chenvictor acquiredhemophiliaainthesettingofdualanticoagulationtherapyandlupusanticoagulantacasereport AT robylaurenc acquiredhemophiliaainthesettingofdualanticoagulationtherapyandlupusanticoagulantacasereport AT wentzelstephanie acquiredhemophiliaainthesettingofdualanticoagulationtherapyandlupusanticoagulantacasereport AT limingjia acquiredhemophiliaainthesettingofdualanticoagulationtherapyandlupusanticoagulantacasereport AT jonesnicholas acquiredhemophiliaainthesettingofdualanticoagulationtherapyandlupusanticoagulantacasereport |